Pinealon is a synthetic tripeptide made of glutamic acid, aspartic acid and arginine (Glu-Asp-Arg), also called the EDR peptide. It comes from the Russian bioregulator research programme and is discussed as a short peptide of interest for neural and longevity research.

What does research suggest about Pinealon?

Some neuroprotective effects have been reported, mainly in animal and in-vitro studies from the research groups that originally described it. Independent replication is limited, so the evidence is best regarded as preclinical and weak rather than clinically established in humans.

Is Pinealon approved or FDA-approved?

No. Pinealon is not an approved medicine in the United States, the United Kingdom or the European Union. It is a research-status compound and is not a validated therapy where it is unapproved.

Human safety data for Pinealon are weak and its long-term profile is not well characterised. Because rigorous safety studies are lacking, its risks are not fully understood and claims about tolerability should be treated with caution.

What are the potential side effects of Pinealon?

There is no well-established side-effect profile for Pinealon in humans, and its long-term effects are unknown. The absence of documented side effects reflects a lack of controlled study data, not proof of safety.

Pinealon is not sold as an approved drug and is generally handled as a research-status material, with availability restricted in many markets. Its legal status varies by country, and research-market material is typically unregulated and unverified for quality or purity.

How does Pinealon relate to other 'bioregulator' peptides like Epitalon?

Both come from the same Russian short-peptide bioregulator research tradition that grew out of studying pineal-gland extracts. Pinealon is the tripeptide Glu-Asp-Arg (often labelled 'EDR'), while Epitalon is a different tetrapeptide. They are frequently grouped together in longevity discussions, but they are distinct molecules with separate (and each fairly thin) evidence bases.

Why is Pinealon popular despite weak evidence?

Most of its appeal comes from the broader 'bioregulator' narrative and its association with anti-ageing and neuro-support claims, rather than from robust independent human trials. A common misconception is that being a small natural-looking peptide sequence makes it inherently safe or proven; in reality the compound's supporting data is limited and largely traces back to a single research lineage.

What does 'research status' mean for how it is handled in a lab setting?

It means Pinealon is not an approved medicine and is sold to researchers as an unverified material, not a tested therapy. Purity and identity of research-market peptides are not guaranteed, and reconstituted peptides are generally sensitive to heat, light and repeated freeze-thaw. This page is educational only and does not provide handling, dosing or usage instructions.

Where can I buy Pinealon and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Longevity / Bioregulator

Buy Pinealon – Vendors, Prices, Testing and Evidence

Buy Pinealon

Also known as: EDR peptide

Evidence grade D — Anecdotal

Short answer

A short 'bioregulator' peptide discussed for neuro/longevity effects. Evidence is weak and largely from one research tradition.

Where can you buy Pinealon?

No peptide-specific vendor offer is currently verified. The vendor catalogue link is provided for discovery only and does not assert availability.

What is known?

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Russian bioregulator research programme.

What is not established?

Weak; limited independent replication.

Safety

Human safety data is weak; treat claims with caution.

Regulatory status

Not an approved medicine. Research status.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Vendor comparison

Buy Pinealon: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is it?

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Russian bioregulator research programme.

Research and evidence

Pinealon is a synthetic tripeptide, composed of the amino acids glutamic acid, aspartic acid and arginine (Glu-Asp-Arg, hence the alias "EDR peptide"). It originates from the Russian "bioregulator" research programme, a tradition that has developed a family of very short peptides proposed to act as signalling molecules within specific tissues. Pinealon is discussed within this framework as a peptide of interest for the nervous system and for longevity-related research. On peptides.cx it is catalogued as a Longevity / Bioregulator compound with a low evidence grade, reflecting the current state of independent science rather than the promotional claims that circulate around it.

The reason Pinealon attracts attention is the broader bioregulator hypothesis: that short peptides may interact with gene-expression pathways and thereby influence how cells behave, including in neural tissue. Some neuroprotective effects have been reported, but it is important to be precise about where that evidence comes from. The bulk of the published work originates from the research groups that first described the compound, and there is limited independent replication in the wider scientific literature. Animal and in-vitro reports form most of the basis for the neuroprotective narrative; robust, well-controlled human clinical trials establishing meaningful benefit are lacking. In evidence terms, Pinealon should be understood as preclinical and largely single-tradition, not as an established therapeutic.

Pinealon is not an approved medicine in major regulatory jurisdictions such as the United States, the United Kingdom or the European Union; it is best described as a research-status compound. Human safety data are weak, and its long-term profile is not well characterised, so any claims about benefit or tolerability should be treated with caution. This page is an educational reference intended to summarise what Pinealon is, why it is researched, and how strong (or weak) the underlying evidence actually is. It is not medical advice, and it does not provide dosing, protocols or sourcing guidance. Anyone considering peptides for a health reason should speak with a qualified, licensed healthcare professional.

Evidence grade: D

Weak; limited independent replication. Some neuroprotective claims from originating groups.

Human evidence

Weak; limited independent replication.

Animal and preclinical evidence

Some neuroprotective claims from originating groups.

Proposed mechanisms

Proposed peptide-bioregulator effects on gene expression

Safety concerns and known side effects

Human safety data is weak; treat claims with caution.

Unknown long-term profile

Regulatory status

Not an approved medicine. Research status.

Pinealon research timeline

1970s–1980s
Soviet-era research on peptide extracts from organs (including the pineal gland) launches the 'bioregulator' programme that later gives rise to short synthetic peptides like Pinealon.
1990s
Researchers move from crude tissue extracts toward defined ultra-short synthetic peptides, the lineage from which the tripeptide Glu-Asp-Arg (marketed as Pinealon / 'EDR peptide') is drawn.
2000s
The originating Russian research groups describe Pinealon as a synthetic tripeptide and publish preclinical work proposing neuroprotective and gene-expression effects.
2010s
Further preclinical (largely cell and animal) reports continue to come mainly from the same research tradition, with little independent replication elsewhere.
early 2020s
Pinealon circulates on the research-chemical market as a 'longevity/bioregulator' compound; it remains unapproved as a medicine and human evidence stays weak.

Frequently asked questions about Pinealon

What is Pinealon?: Pinealon is a synthetic tripeptide made of glutamic acid, aspartic acid and arginine (Glu-Asp-Arg), also called the EDR peptide. It comes from the Russian bioregulator research programme and is discussed as a short peptide of interest for neural and longevity research.
What does research suggest about Pinealon?: Some neuroprotective effects have been reported, mainly in animal and in-vitro studies from the research groups that originally described it. Independent replication is limited, so the evidence is best regarded as preclinical and weak rather than clinically established in humans.
Is Pinealon approved or FDA-approved?: No. Pinealon is not an approved medicine in the United States, the United Kingdom or the European Union. It is a research-status compound and is not a validated therapy where it is unapproved.
Is Pinealon safe?: Human safety data for Pinealon are weak and its long-term profile is not well characterised. Because rigorous safety studies are lacking, its risks are not fully understood and claims about tolerability should be treated with caution.
What are the potential side effects of Pinealon?: There is no well-established side-effect profile for Pinealon in humans, and its long-term effects are unknown. The absence of documented side effects reflects a lack of controlled study data, not proof of safety.
Is Pinealon legal?: Pinealon is not sold as an approved drug and is generally handled as a research-status material, with availability restricted in many markets. Its legal status varies by country, and research-market material is typically unregulated and unverified for quality or purity.
How does Pinealon relate to other 'bioregulator' peptides like Epitalon?: Both come from the same Russian short-peptide bioregulator research tradition that grew out of studying pineal-gland extracts. Pinealon is the tripeptide Glu-Asp-Arg (often labelled 'EDR'), while Epitalon is a different tetrapeptide. They are frequently grouped together in longevity discussions, but they are distinct molecules with separate (and each fairly thin) evidence bases.
Why is Pinealon popular despite weak evidence?: Most of its appeal comes from the broader 'bioregulator' narrative and its association with anti-ageing and neuro-support claims, rather than from robust independent human trials. A common misconception is that being a small natural-looking peptide sequence makes it inherently safe or proven; in reality the compound's supporting data is limited and largely traces back to a single research lineage.
What does 'research status' mean for how it is handled in a lab setting?: It means Pinealon is not an approved medicine and is sold to researchers as an unverified material, not a tested therapy. Purity and identity of research-market peptides are not guaranteed, and reconstituted peptides are generally sensitive to heat, light and repeated freeze-thaw. This page is educational only and does not provide handling, dosing or usage instructions.
Where can I buy Pinealon and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

BioregulatorsLongevity

Sources

Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes — Rejuvenation Research · PubMed

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10